Biogen BIIB

NAS: BIIB | ISIN: US09062X1037   14/10/2026
232,83 USD (+1,72%)
(+1,72%)   14/10/2026

2 oktober 2026 · Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus · Persbericht

17 september 2026 · Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN · Persbericht

4 september 2026 · Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) · Persbericht

1 september 2026 · Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) · Persbericht

24 augustus 2026 · LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease · Persbericht

7 augustus 2026 · Biogen Completes Acquisition of RayThera Inc. · Persbericht

16 juli 2026 · Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide · Persbericht

15 juli 2026 · Biogen Appoints Michael J. Parini as Chief Legal Officer · Persbericht

14 juli 2026 · LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment · Persbericht

13 juli 2026 · FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease · Persbericht

12 juli 2026 · LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® (AAIC®) 2026 · Persbericht

29 juni 2026 · Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen · Persbericht

18 juni 2026 · Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc. · Persbericht

4 juni 2026 · Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy · Persbericht

4 juni 2026 · EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus · Persbericht

22 mei 2026 · Biogen Inc. (BIIB) Securities Fraud Investigation - Levi & Korsinsky · Persbericht

18 mei 2026 · BIIB SHAREHOLDER INVESTIGATION: SueWallSt Investigates Biogen Inc. for Possible Securities Law Violations · Persbericht

16 mei 2026 · Biogen Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Biogen Inc. (BIIB) · Persbericht

14 mei 2026 · Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease · Persbericht

8 mei 2026 · Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease · Persbericht

Mijn selecties